1 / 28

The Critical Value of Infectious Diseases Specialists

The Critical Value of Infectious Diseases Specialists. Steven K. Schmitt, MD, FIDSA, FACP Vice Chair, Medicine Institute Cleveland Clinic. Value is central to reform. Conversation in health care reform is focused on Value Critical questions: What value does each specialty contribute?

roddy
Télécharger la présentation

The Critical Value of Infectious Diseases Specialists

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Critical Value of Infectious Diseases Specialists Steven K. Schmitt, MD, FIDSA, FACP Vice Chair, Medicine Institute Cleveland Clinic

  2. Value is central to reform Conversation in health care reform is focused on Value Critical questions: • What value does each specialty contribute? • Can specialty care actually bend the cost curve? Value = Quality Cost

  3. ID Specialists Contribute to Achieving “The Triple Aim” * Institute for Healthcare Improvement. See more information at http://www.ihi.org/offerings/Initiatives/TripleAIM/Pages/default.aspx

  4. Evidence for ID Value • Link between ID interventions and positive patient outcomes.* • When the attending physician follows ID recommendations: • Patients are more often correctly diagnosed • Have shorter length of stays • Have fewer complications • Use antibiotics more judiciously * See supporting literature cited in Schmitt et al. Infectious Diseases Specialty Intervention Is Associated With Decreased Mortality and Lower Healthcare Costs. Clin Infect Dis. (2013) doi: 10.1093/cid/cit610 First published online: September 25, 2013

  5. Objective of New Research: Proof of Value • To generate more robust data regarding the impact of ID consultation using a national claims database • Outcomes significant in the health care reform conversation • Mortality • Readmission rate • Length of stay • Resource utilization

  6. Methods The matched sample included 61,680 ID cases and 65,192 non-ID cases

  7. Results: NO ID vs ID Abbreviations: ICU, Intensive Care Unit; ACH, Acute care hospital; PAC, Post acute care; OR, odds ratio; %Δ, percent difference. a Only patients with one or more ICU days. b Excludes patients expiring in the hospital. “Having an ID Specialist involved in the care of a patient with a severe infection will lead to better outcomes”

  8. Results: “Early” vs “Late” Abbreviations: ICU, Intensive Care Unit; ACH, Acute care hospital; PAC, Post acute care; OR, odds ratio; %Δ, percent difference. a Only patients with one or more ICU days. b Excludes patients expiring in the hospital. “Early involvement of an ID Specialist in the care of patients with severe infection will lead to better outcomes with lower costs”

  9. Limitations • Measuring hospital mortality may overstate the impact of ID intervention on mortality • Unobserved reasons for selection of patients to receive an ID intervention may confound the results • The PSM methodology excludes some of the sickest people in the ID intervention group, because they had no matches from the non-ID intervention group (patients who were too dissimilar were not included in the analysis) • The results therefore may not fully reflect the impact of ID interventions, since it did not take the care for these severe cases into account

  10. Implications • ID involvement leads to improved patient outcomes AND Early ID interventions result in improved outcomes and reduced costs • Patients seen by an ID specialist are • 9% less likely to die in the hospital • 12% less likely to die post-discharge • Spend 3.7 % less time in the ICU • These results suggest a critical role for ID consults for select, severe infections • Consider these results in light of current core measures such as “all-cause” mortality, pneumonia, CLABSI, and CAUTI

  11. Other areas where ID can add value • ID specialist-led Antimicrobial Stewardship and Diagnostic Stewardship • Transitions of care for complex infections • Outpatient Parenteral Antimicrobial Therapy (OPAT) • Employee health • Resource management and Microbiology laboratory oversight • Public health

  12. Infection preventionAn economist’s view Scott (2009) Benefits of prevention: http://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf

  13. Antimicrobial stewardship • Beardsley et al (2012): costs over 11 years of stewardship program • Average cost savings (drug savings - program cost): $920,070 to $2,064,441 per year. Beardsley JR, et al. Infect Control Hosp Epidemiol. 2012 Apr;33(4):398-400.

  14. Infection prevention and antimicrobial stewardship: why ID? • Clinical boots on the ground • Outbreak detection • Separation of problems from rumors • Management of complex and drug-resistant infections Extensive training in infections, antibiotics, interpretation of microbiologic data

  15. Infection prevention and antimicrobial stewardship: why ID? • Consult all over hospital: • Accustomed to cross-disciplinary collaboration • Problem-solvers • Evidence-based and data aware

  16. OPAT transitions and stewardship • Shrestha NK et al (2012): 263 OPAT consultation requests • Antimicrobial treatment optimization: right drug! Parenteral atb’s often not recommended • Change in diagnosis: right disease! • Same provider transition, inpatient to outpatient setting: right doc! Shrestha NK, Bhaskaran A, Scalera NM, Schmitt SK, Rehm SJ, Gordon SM. J Hosp Med. 2012 May-Jun;7(5):365-9. Shrestha NK, Bhaskaran A, Scalera NM, Schmitt SK, Rehm SJ, Gordon SM. Infect Control Hosp Epidemiol. 2012 Apr;33(4):401-4.

  17. OPAT transitions and stewardship • Longitudinal follow-up • Lab monitoring • First line of communication • Patients, caregivers • Prevention, amelioration, management of: • Adverse drug effects • Flares or ID and non-ID conditions • Venous access complications • Prevention of ED visits and readmissions

  18. Utilization of other key resources • Diagnostic Stewardship and Appropriate use • Lab testing • Microbiology lab • Radiology

  19. Population Health Response Management • Exposures • Infected healthcare worker • Vaccine-preventable diseases • TB diagnosis, management, and prevention • Bioterrorism and natural disasters Communications • Internal • Development of policy and guidance • External • Providing conduit to local and state health departments

  20. Innovation by collaboration on value • Gain-sharing agreements • Co-management services agreements Please come to talk tomorrow: Dr. Ron Nahass

  21. Put us to work for you • ID ready to collaborate with you as the system evolves in an era of transparency, measurement, and value-based payment

  22. What does ID bring to your team? • Combination of clinical and epidemiologic expertise • Improved clinical outcomes: • Save lives! • Save your reputation! • Prevention of hospital-acquired infection • CLABSI, CAUTI, SSI = $ • Reportable measures, pay for performance Population health

  23. What does ID bring to your team? • Improved resource use • Improved care transitions • Collaborative skill-set • Problem solvers

  24. Back-Up Slides

  25. Propensity Score Matching ID vs No ID Paired Cases via PSM

  26. ID plays a leading role in health care systems • Core measures such as pneumonia, CLABSI, CAUTI-maximize reimbursement and save lives! • Antimicrobial stewardship programs - reduce drug costs and curtail resistance! • Infection prevention - save lives and reduce costs! • Care transitions - right diagnosis, right drugs, effective follow-up in outpatient parenteral antibiotic programs.

  27. Put us to work for you!

More Related